Form 4: Oncotelic CEO Awarded Performance-Based Stock

Oncotelic Therapeutics' Chairman and CEO, Vuong Trieu, received 4,426 shares of Series A Convertible Preferred Stock as compensation for achieving performance milestones.

Summary

• Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc. (OTLC), acquired 4,426 shares of Series A Convertible Preferred Stock.
• The transaction occurred on January 22, 2026.
• These shares were issued as compensation for achieving performance milestones under a Restricted Stock Agreement dated January 21, 2026.
• Each share of Series A Convertible Preferred Stock is convertible into 1,000 shares of Common Stock at the holder's option.
• The underlying securities for the acquired preferred stock represent 4,426,000 shares of Common Stock.
• Following this transaction, Dr. Trieu directly beneficially owns 8,491 shares of Series A Convertible Preferred Stock.

Sentiment

Score: 7

Explanation: The filing indicates that the CEO achieved performance milestones, leading to compensation. This is generally positive as it suggests progress within the company and aligns management incentives. However, it's a routine compensation event rather than a significant market-moving announcement.

Positives

• Chairman and CEO Vuong Trieu received compensation for achieving performance milestones, indicating successful execution of company objectives.
• The issuance of performance-based equity aligns management's interests with long-term shareholder value.

Negatives

• No explicit negative information is typically disclosed in a Form 4 filing, which reports insider transactions.

Risks

• Form 4 filings primarily report insider transactions and do not typically detail company-specific risks.

Future Outlook

This Form 4 filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026.

Industry Context

This insider transaction report is specific to Oncotelic Therapeutics and its executive compensation structure. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The transaction involves the issuance of Series A Convertible Preferred Stock to Vuong Trieu, the Chairman and CEO, making it a related party transaction as it is compensation to an insider.

Stakeholder Impact

• Shareholders: The issuance of convertible preferred stock could lead to future dilution if converted into common stock, but it also signals that management is meeting performance targets, which could be viewed positively.
• Management: Dr. Trieu directly benefits from the compensation, aligning his financial interests with the company's performance.

Next Steps

• The filing does not specify any future actions, events, or milestones beyond the reported transaction.

Key Dates

Keywords

Oncotelic Therapeutics, OTLC, Vuong Trieu, SEC Form 4, Insider Transaction, Executive Compensation, Convertible Preferred Stock, Performance Milestones, Equity Award